Aktienanalyse zu Lantern Pharma Inc (LTRN)LTRNLantern Pharma Inc

Lantern Pharma Inc. is an artificial intelligence (AI) company. The Company is developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, leverages over 200 billion oncology-focused data points and a library of 200+ ML algorithms. It is engaged in the development of its pipeline of drug candidates that span multiple cancer indications, including both solid tumors and blood cancers and an antibody drug conjugate program. Its portfolio includes a Phase II clinical program (LP-300) in NSCLC focused on never-smokers and non-smokers with the EGFR exon 21 L858R mutation; planned Phase I b/II trials (LP-184) in precision, biomarker-defined solid tumors, and an ongoing Phase II program in hematologic malignancies and adult soft tissue sarcomas (LP-284). It is also focused on the clinical execution of its therapies for CNS and brain cancers through Starlight Therapeutics Inc. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Lantern Pharma Inc is not a good buy right now due to its current price of 0.5664, which is close to its 52-week low of 0.50, and an RSI of 34.967 indicating oversold conditions. The company has reported a staggering year-to-date change of -81.79%, reflecting severe financial distress and lack of revenue generation.